Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis.

about

Inhibition of EGFR Signaling Protects from Mucormycosis

P2860

Q58207282-2618D42C-1347-486C-BA86-A59E779D89A3

P2860

Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis.

Item

http://www.wikidata.org/entity/Q39575509

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Posaconazole: an emerging ther ...... -orbito-cerebral mucormycosis.

@en

Posaconazole: an emerging ther ...... -orbito-cerebral mucormycosis.

@nl

type

Item

label

Posaconazole: an emerging ther ...... -orbito-cerebral mucormycosis.

@en

Posaconazole: an emerging ther ...... -orbito-cerebral mucormycosis.

@nl

prefLabel

Posaconazole: an emerging ther ...... -orbito-cerebral mucormycosis.

@en

Posaconazole: an emerging ther ...... -orbito-cerebral mucormycosis.

@nl

P1476

Posaconazole: an emerging ther ...... o-orbito-cerebral mucormycosis

@en

P2093

Abi Manesh

http://www.w3.org/2001/XMLSchema#string

Anand Zachariah

http://www.w3.org/2001/XMLSchema#string

Binu Mathew

http://www.w3.org/2001/XMLSchema#string

George M Varghese

http://www.w3.org/2001/XMLSchema#string

Lalee Varghese

http://www.w3.org/2001/XMLSchema#string

P2860

Zygomycetes in human disease

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Posaconazole as salvage therapy for zygomycosis.

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.

Antifungal therapeutic drug monitoring: established and emerging indications.

Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature.

The emerging epidemiology of mould infections in developing countries.

P304

765-772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/MYC.12529

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

V Rupa

Ajoy John

P577

2016-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27443253

http://www.w3.org/2001/XMLSchema#string

Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis.

about

P2860

P2860

Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698